{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": {
    "pdf_name": "FlublokPI",
    "source_pdf": "data/clinical_files/FlublokPI.pdf",
    "total_pages": 5,
    "total_blocks": 54,
    "total_characters": 25335
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "3. Keitel WA, Treanor JJ, El Sahly HM, et.al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among persons \u226565 years old. Vaccine. 2009, Vol. 28, pp. 379-385.",
      "relevance_explanation": "This reference is cited in the document as a study that directly compares the immunogenicity (antibody response) of recombinant (higher-dose) and standard egg-based influenza vaccines in older adults, supporting the claim that the recombinant vaccine may induce a more robust antibody response."
    },
    {
      "id": 2,
      "quote": "Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of Flublok trivalent recombinant baculovirus expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011, Vol. 29, pp. 2272-2278.",
      "relevance_explanation": "This referenced study evaluates the immunogenicity of Flublok, a higher-dose recombinant flu vaccine, in adults aged 50-64, providing evidence relevant to the claim that such vaccines may induce a more robust antibody response compared to standard egg-based vaccines."
    }
  ],
  "model_used": "gpt-4.1"
}